Document is current
Any future updates will be listed below
-
Authors
Sirvent, Pascal https://orcid.org/0000-0002-3921-0799
Langhi, Cedric https://orcid.org/0000-0002-7732-3882
Vallier, Marie https://orcid.org/0000-0002-7188-7070
Oliveira, Arsênio Rodrigues
Croyal, Mikael
Otero, Yolanda F.
Chavanelle, Vivien https://orcid.org/0000-0003-0761-3355
Michaux, Arnaud
Bargetto, Maxime
Le Joubioux, Florian
Maugard, Thierry
Cazaubiel, Murielle
Bouchard-Mercier, Annie
Sapone, Véronique
Pereira, Bruno
Dutheil, Frédéric
Peltier, Sebastien L.
Bard, Jean-Marie
- License Information
-
More Information
Article History
Received: 14 February 2025
Revised: 18 September 2025
Accepted: 2 December 2025
First Online: 24 December 2025
Competing interests
: PS, CL, MV, YFO, VC, AM, MB, FLJ, MC, ABM and VS are employees of Valbiotis. SLP is CEO of Valbiotis. TM and JMB are members of the scientific committee and stock shareholder of Valbiotis.
: The study followed Good Clinical Practice (GCP) guidelines and received approval from national and local ethics committees. Written informed consent was obtained from all participants before enrollment. The procedures were in accordance with the Declaration of Helsinki 1975, as revised in 1983. ClinicalTrials.gov Identifier: NCT04760951 ( ).
